diphenhydramine has been researched along with Alcoholism in 11 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
Excerpt | Relevance | Reference |
---|---|---|
"We created acute pancreatitis in cats by instilling ethanol (20 ml of a 40% solution) into the stomach and then perfusing activated pancreatic enzymes through the main pancreatic duct." | 1.28 | Treatment of acute alcoholic pancreatitis in cats. ( Reber, HA; Singh, SM, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (54.55) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (18.18) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Bogenschutz, MP | 2 |
Ross, S | 2 |
Bhatt, S | 1 |
Baron, T | 2 |
Forcehimes, AA | 2 |
Laska, E | 1 |
Mennenga, SE | 2 |
O'Donnell, K | 1 |
Owens, LT | 2 |
Podrebarac, S | 1 |
Rotrosen, J | 2 |
Tonigan, JS | 1 |
Worth, L | 1 |
O'Donnell, KC | 1 |
Podrebarac, SK | 1 |
Erbe, S | 1 |
Bschor, T | 1 |
Scanlon, KA | 1 |
Stoppacher, R | 1 |
Blum, LM | 1 |
Starkey, SJ | 1 |
Pardo, MP | 2 |
Hall, TB | 2 |
Plueckhahn, VD | 1 |
Singh, SM | 1 |
Reber, HA | 1 |
Miller, TP | 1 |
Taylor, JL | 1 |
Tinklenberg, JR | 1 |
Miller, NS | 1 |
Goodwin, DW | 1 |
Jones, FC | 1 |
Gabrielli, WF | 1 |
Anand, MM | 1 |
Guz, I | 2 |
Segre, CD | 1 |
Ribas, JC | 2 |
de Fortes, JR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence[NCT02061293] | Phase 2 | 95 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms[NCT06160232] | Phase 2 | 62 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists[NCT03497442] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)
Intervention | drinks per day (Mean) |
---|---|
Psilocybin | 2.77 |
Diphenhydramine | 2.19 |
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
Intervention | drinks per day (Mean) |
---|---|
Psilocybin | 1.17 |
Diphenhydramine | 2.26 |
The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)
Intervention | drinks per day (Mean) |
---|---|
Psilocybin | 5.2 |
Diphenhydramine | 4.38 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 52.98 |
Diphenhydramine | 45.99 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 29.39 |
Diphenhydramine | 42.83 |
The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 78.03 |
Diphenhydramine | 71.68 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Baseline (Week 4)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 24.11 |
Diphenhydramine | 21.31 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 9.71 |
Diphenhydramine | 23.57 |
The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Screening (Week 0)
Intervention | percentage of days (Mean) |
---|---|
Psilocybin | 56.48 |
Diphenhydramine | 48.57 |
The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 33 Up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 62.5 |
Diphenhydramine | 40 |
The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 33.3 |
Diphenhydramine | 11.1 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 89.6 |
Diphenhydramine | 64.4 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 83.3 |
Diphenhydramine | 71.1 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 60.4 |
Diphenhydramine | 40 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 60.4 |
Diphenhydramine | 40 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 37.5 |
Diphenhydramine | 17.8 |
For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 29.92 |
Diphenhydramine | 13.3 |
The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 33 up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 47.9 |
Diphenhydramine | 24.4 |
The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36
Intervention | Percentage of participants (Number) |
---|---|
Psilocybin | 22.9 |
Diphenhydramine | 8.9 |
15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Baseline (Week 4)
Intervention | score on a scale (Mean) |
---|---|
Psilocybin | 20.26 |
Diphenhydramine | 21.6 |
15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Week 36
Intervention | score on a scale (Mean) |
---|---|
Psilocybin | 6.59 |
Diphenhydramine | 13 |
2 reviews available for diphenhydramine and Alcoholism
Article | Year |
---|---|
[Diphenhydramine addiction and detoxification. A systematic review and case report].
Topics: Adult; Aged; Alcoholism; Comorbidity; Diphenhydramine; Dose-Response Relationship, Drug; Drug Admini | 2013 |
Genetic implications of the alcohol-induced flushing phenomenon in Orientals.
Topics: Acetaldehyde; Alcoholism; Asian People; Cimetidine; Diphenhydramine; Ethanol; Female; Histamine; Hum | 1981 |
3 trials available for diphenhydramine and Alcoholism
Article | Year |
---|---|
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.
Topics: Alcohol Drinking; Alcoholism; Diphenhydramine; Humans; Psilocybin; Treatment Outcome | 2022 |
A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics.
Topics: Adult; Alcoholism; Arousal; Attention; Diazepam; Diphenhydramine; Discrimination Learning; Humans; M | 1988 |
Antihistamine blockade of alcohol-induced flushing in orientals.
Topics: Adolescent; Adult; Alcoholism; Asian People; Blood Pressure; Cimetidine; Diphenhydramine; Ethanol; F | 1988 |
6 other studies available for diphenhydramine and Alcoholism
Article | Year |
---|---|
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu | 2022 |
Comprehensive Duloxetine Analysis in a Fatal Overdose.
Topics: Aged; Alcoholism; Amitriptyline; Depression; Diphenhydramine; Drug Overdose; Duloxetine Hydrochlorid | 2016 |
Alcohol and road safety: Geelong experience 1967 to 1978.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Australia; Automobile Dri | 1978 |
Treatment of acute alcoholic pancreatitis in cats.
Topics: Acute Disease; Alcoholism; Animals; Cats; Cimetidine; Diphenhydramine; Drug Therapy, Combination; Fe | 1990 |
[Use of the combination methaqualone-diphenyhydramine in ambulatory patients].
Topics: Adolescent; Adult; Alcoholism; Ambulatory Care; Anxiety; Diphenhydramine; Female; Humans; Male; Meth | 1969 |
[Therapeutic test with a new non-barbiturate hypnotic].
Topics: Adolescent; Adult; Alcoholism; Diphenhydramine; Humans; Hypnotics and Sedatives; Male; Mental Disord | 1968 |